Clinical trials: Lipoprotein(a)
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Hypercholesterolemia
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
A multicenter study to evaluate safety and efficacy of inclisiran in Asian patients with ASCVD or ASCVD high risk and elevated LDL-C
- Trial name
- NCT04765657
- Testing
- inclisiran sodium
- Where
- 45 sites in China, Singapore and 2 more
- Volunteers
- 345 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia
A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-PCSSC in subjects with elevated LDL-C.
- Trial name
- NCT02314442
- Testing
- ALN-PCSSC, Sterile Normal Saline (0.9% NaCl)
- Where
- 2 sites in United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Hypercholesterolemia, Coronary Heart Disease
Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg
The purpose of this study is to compare 6 weeks of treatment with rosuvastatin alone compared with 6 weeks of treatment of rosuvastatin combined with ezetimibe in achieving low density lipoprotein level goals.
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Atherosclerosis
- Trial name
- EXPLORER (NCT00653445)
- Testing
- Rosuvastatin, Ezetimibe
- Sponsor
- AstraZeneca
Hypercholesterolemia
A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)
A study to evaluate the cholesterol-lowering effects of ezetimibe in participants with primary hypercholesterolemia (high cholesterol) after eating a meal that is high in cholesterol.
- Trial name
- NCT00101439
- Testing
- ezetimibe
- Volunteers
- 58 people
- Sponsor
- Organon and Co
Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease…
- Trial name
- NCT06164730
- Testing
- VERVE-102
- Where
- 27 sites in United States, Australia and 4 more
- Volunteers
- 85 people
- Sponsor
- Verve Therapeutics, Inc.
Elevated Lipoprotein(a)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events
This is a randomized, double-blind, placebo-controlled Phase II trial evaluating the efficacy and safety of oral SAL0137 in adults with elevated Lp(a) and high cardiovascular risk.
- Trial name
- NCT07729475
- Testing
- SAL0137 Dose 1, SAL0137 Dose 2, SAL0137 Dose 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Lipoprotein Disorder
A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]
The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.
- Trial name
- NCT05565742
- Testing
- LY3819469
- Where
- 80 sites in United States, Argentina and 8 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Elevated Lipoprotein(a)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS APO(a)-LRx (ISIS 681257) given to healthy volunteer subjects.
- Trial name
- NCT02414594
- Testing
- IONIS-APO(a)-LRx, Sterile Normal Saline (0.9% NaCl)
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hyperlipoproteinemia (a)
An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This non-randomized, open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants in Germany with hyperlipoproteinemia(a) and established cardiovascular disease who have successfully completed the…
- Trial name
- OLE (NCT05900141)
- Testing
- Pelacarsen
- Where
- 9 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
A Diabetes Study to Treat A Population Previously Not at Target
This study will assess if customizing the start dose of rosuvastatin appropriate for the degree of LDL-C reduction required, would achieve LDL-C target of ≤ 2.0 mmol/L quickly with either no titration or just one titration step…
- Trial name
- ADAPT (NCT00747149)
- Testing
- Rosuvastatin
- Where
- 84 sites in Canada
- Volunteers
- 598 people
- Sponsor
- AstraZeneca
Familial Lipoprotein Lipase Deficiency
Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]
LPLD is a rare autosomal recessive disorder, characterized by the presence of marked chylomicronemia and hence hypertriglyceridemia.
- Trial name
- NCT01109498
- Testing
- Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Mycophenolate mofetil, cyclosporine
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Amsterdam Molecular Therapeutics
Cardiovascular Disease
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C.
- Trial name
- AZURE-LDL (NCT07000123)
- Testing
- AZD0780
- Where
- 404 sites in United States, Argentina and 20 more
- Volunteers
- 3,103 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Multiple-dose study to measure pharmacokinetics, pharmacodynamics and safety of bempedoic acid in pediatric participants 6 to 17 years of age with HeFH.
- Trial name
- CLEAR Path 1 (NCT05694260)
- Testing
- Bempedoic acid
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 31 people
- Sponsor
- Esperion Therapeutics, Inc.
Elevated Lipoprotein(a)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-APO(a)Rx given to participants with high lipoprotein(a) for 12 weeks.
- Trial name
- NCT02160899
- Testing
- ISIS-APO(a)Rx
- Where
- 13 sites in Canada, Denmark and 3 more
- Volunteers
- 64 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypercholesterolemia
Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)
The purpose of this 24 week study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood (dyslipidemia).
- Trial name
- NCT00080275
- Testing
- Niacin Extended-Release and simvastatin Tablets
- Volunteers
- 600 people
- Sponsor
- Kos Pharmaceuticals
ASCVD, Elevated Cholesterol
Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability…
- Trial name
- ORION-10 (NCT03399370)
- Testing
- Inclisiran Sodium
- Where
- 145 sites in United States
- Volunteers
- 1,561 people
- Sponsor
- The Medicines Company
Elevated Lipoprotein(a), Cardiovascular Diseases
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel
This is a single center, open label, single sequence, two treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of multiple doses of clopidogrel
- Trial name
- NCT03392051
- Testing
- ISIS 681257, Clopidogrel
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Akcea Therapeutics
Hypercholesterolemia, Dyslipidaemia
Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)
The purpose of this study is to compare the effect of 6 weeks of treatment with Rosuvastatin with 6 weeks of treatment with Atorvastatin in African American subjects with hypercholesterolemia.
- Trial name
- ARIES (NCT00653744)
- Testing
- Rosuvastatin, Atorvastatin
- Volunteers
- 1,700 people
- Sponsor
- AstraZeneca
Dyslipidaemias, Dyslipidaemia
GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol
The purpose of this clinical research study is to compare up to 3 doses of an investigational drug GW501516 to placebo (an inactive pill that looks like GW501516) to see if it is safe, well tolerated and effective in improving…
- Trial name
- NCT00158899
- Testing
- GW501516 oral tablets
- Where
- 64 sites in Belgium, Denmark and 9 more
- Volunteers
- 424 people
- Sponsor
- GlaxoSmithKline